Efanesoctocog alfa | m-entrepreneurship.com

Product Name :
Efanesoctocog alfa

Search keywords :
von Willebrand Factor

drugId :
null

Target Vo:
Coagulation factor X

Target Vo Short Name :
F10

Moa_Name:
Factor VIII replacements

First Approval Country :
United States

First Approval Date Filter:
2023

Origin Company_Name :
Amunix Pharmaceuticals Inc

Active Company_Name :
Biogen Inc

Active Indication_Name:
Hemophilia A

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Phase 3 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Beta-Catenin Antibody
Src Antibody
Phospho-RSK4 (Ser232) Antibody: Phospho-RSK4 (Ser232) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 84 kDa, targeting to Phospho-RSK4 (Ser232). It can be used for WB,ICC/IF assays with tag free, in the background of Human.

Author: Betaine hydrochloride

Related Posts